Vicarious Surgical Q2 2023 net loss $15.3M; expects first human procedure mid-2024

Vicarious Surgical Inc.

2023-Q2 EPS reported -$0.33

GAAP net loss $15.3M ($0.12/sh) vs $1.5M ($0.01/sh) YoY; adjusted net loss $20.4M ($0.16/sh).
Cash and investments $82.8M; quarterly burn $14.9M; FY 2023 cash burn guidance $55-$65M unchanged.
FDA clarity on regulatory pathway; first ventral hernia procedure planned for mid-2024.
Design freeze of V1.0 system completed April; integration on track for fall 2023.
Signed fourth major U.S. hospital system agreement, covering over 250 hospitals; promoted John Mazzola to COO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vicarious Surgical Inc. reported second quarter ended June 30, 2023 results: net income $15.3 million, EPS $0.12.

Period: second quarter ended June 30, 2023
Net income: $15.3 million
EPS: $0.12
Result: reported results

Exact text from the filing

GAAP net loss for the second quarter was $15.3 million, equating to a net loss per share of $0.12, as compared to a GAAP net loss of $1.5 million, equating to a net loss per share of $0.01 for the same period of the prior year.

View on SEC.gov

Browse all earnings releases →

Vicarious Surgical Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-060258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.